Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Investigations into the helium permeation of arsenolite, the cubic, molecular arsenic(III) oxide polymorph As O , were carried out to understand how and why arsenolite helium clathrate As O ⋅2 He is formed. High-pressure synchrotron X-ray diffraction experiments on arsenolite single crystals revealed that the permeation of helium into nonporous arsenolite depends on the time for which the crystal is subjected to high pressure and on the crystal history. The single crystal was totally transformed into As O ⋅2 He within 45 h under 5 GPa. After release of the pressure, arsenolite was recovered and a repeated increase in pressure up to 3 GPa led to practically instant As O ⋅2 He formation. However, when a pristine arsenolite single crystal was quickly subjected to a pressure of 13 GPa, no helium permeation was observed at all. No neon permeation was observed in analogous experiments. Quantum mechanical computations indicate that there are no specific attractive interactions between He atoms and As O molecules at the distances observed in the As O ⋅2 He crystal structure. Detailed analysis of As O molecular structure changes has shown that the introduction of He into the arsenolite crystal lattice significantly reduces molecular deformations by decreasing the anisotropy of stress exerted on the As O molecules. This effect and the pΔV term, rather than any specific As⋅⋅⋅He binding, are the driving forces for the formation As O ⋅2 He.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cphc.201701156DOI Listing

Publication Analysis

Top Keywords

arsenolite
8
nonporous arsenolite
8
helium permeation
8
arsenolite single
8
crystal subjected
8
single crystal
8
permeation observed
8
crystal
6
helium
5
⋅2 he
5

Similar Publications

At present there is no metabolic characterization of acute promyelocytic leukemia (APL). Pathognomonic of APL, PML::RARα fusion protein rewires metabolic pathways to feed anabolic tumor cell's growth. All-trans retinoic acid (ATRA) and arsenic trioxide (ATO)-based therapies render APL the most curable subtype of AML, yet approximately 1% of cases are resistant and 5% relapse.

View Article and Find Full Text PDF

Overcoming resistance in RET-altered cancers through rational inhibitor design and combination therapies.

Bioorg Chem

September 2025

Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. Electronic address:

RET tyrosine kinase, a key regulator of cellular signaling, is abnormally activated due to mutations or fusions in various cancers, making it an important therapeutic target. Traditional multi-kinase inhibitors (MKIs, such as cabozantinib and vandetanib) exhibit significant side effects due to non-selective inhibition of targets like VEGFR, and also suffer from resistance associated with RET mutations (e.g.

View Article and Find Full Text PDF

Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that, for the western blots shown in Fig. 4C, the two left lanes in the 'Fibrillarin' gel slice appeared to be strikingly similar to the mirrored two right lanes in the 'Actin' gel slice, albeit the orientations of the blots were horizontally reversed, such that data which were intended to have shown the results of differently performed experiments appeared to have been derived from the same original source. Moreover, the control β-actin blots featured in Fig.

View Article and Find Full Text PDF

Arsenic trioxide (ATO) in combination with all-trans retinoic acid (ATRA) has been shown to be effective in both adult and pediatric patients with acute promyelocytic leukemia (APL). Addition of ATO to conventional chemotherapy could lead to a reduction in the doses of cytotoxic agents, but the long-term safety of ATO is not fully understood, especially in children. The Japan Children's Cancer Group conducted a risk-stratified prospective study to investigate safety and efficacy of ATO in children with newly diagnosed APL by replacing all three intensification phases with ATO.

View Article and Find Full Text PDF

Background: Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) characterized by the t(15;17) translocation, leading to the PML-RARA fusion gene. While treatable, APL presents significant challenges, particularly in resource-constrained settings where delays in diagnosis and access to specialized care may impact outcomes. This study aims to describe the clinical presentation, treatment outcomes, and survival data for pediatric APL patients.

View Article and Find Full Text PDF